LONDON (Reuters) -Blockbuster weight-loss drug maker Novo Nordisk announced on Thursday research collaborations with two U.S. biotech firms, part of its efforts to stay ahead in big pharma’s race to develop more treatments for cardiometabolic diseases.Novo, a Danish drugmaker whose share price rose 49% last year due to soaring demand for its weight-loss medicine Wegovy, […]